Combination Investigational Cancer Therapies” in Washington, DC, on June 13–14, 2011. The workshop agenda can be found in Appendix B of this report. The workshop convened experts to identify barriers that may be impeding the development of combination investigational cancer therapies as well as to offer ways to overcome those barriers. Workshop presentations and discussions included those that addressed:
• Scientific challenges and opportunities in the codevelopment of investigational therapies;
• Regulatory environment for codevelopment, including the recent Food and Drug Administration (FDA) draft guidance on this topic;
• Cultural and legal issues that affect collaboration;
• Lessons learned from codeveloping human immunodeficiency virus and cancer combination therapies; and
• Current examples that can serve as possible models of collaboration to develop combination cancer therapies.
A key goal of this workshop was to identify potential solutions to improve collaboration and accelerate the development of promising combination investigational cancer therapies. This document is a summary of the workshop. The views expressed in this summary are those of the speakers and discussants, as attributed to them, and are not the consensus views of the workshop participants, nor of the members of the National Cancer Policy Forum.